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Background: Prepulse inhibition (PPI) of the startle response refers to the ability of a weak prestimulus to
transiently inhibit the response to a closely following strong sensory stimulus. PPI provides an operational
index of sensorimotor gating and is reduced, on average, in people with schizophrenia, relative to healthy
people. Given the variable response to Cognitive Behaviour Therapy for psychosis (CBTp) and positive asso-
ciations between pre-therapy brain and cognitive functions and CBT outcome across disorders, we examined
whether pre-therapy level of PPI is associated with clinical outcome following CBTp.
Method: Fifty-six outpatients stable on medication with at least one distressing symptom of schizophrenia
and willing to receive CBTp in addition to their usual treatment were assessed on acoustic PPI. Subsequently,
28 patients received CBTp (CBTp+treatment-as-usual, 23 completers) for 6–8 months and 28 continued
with their treatment-as-usual (TAU-alone, 17 completers). Symptoms were assessed (blindly) at entry and
follow-up.
Results: The CBTp+TAUand TAU-alone groups did not differ demographically, clinically or in PPI at baseline. The
CBTp+TAU group showed improved symptoms relative to the TAU-alone group, which showed no change, at
follow-up. Pre-therapy PPI level correlated positively with post-CBTp symptom improvement.
Conclusions: Relatively intact sensorimotor gating is associated with a good clinical response following a
6–8 months course of NICE compliant CBTp in schizophrenia. Pharmacological or psychological interventions
capable of improving PPI may enhance the effectiveness of CBTp in people with schizophrenia, particularly in
those who fail to show clinical improvement with currently available antipsychotic drugs and adjunctive CBTp.© 2011 Elsevier B.V. Open access under CC BY license. 1. Introduction
Despite marked symptom improvement with the use of antipsy-
chotics in acutely ill patients with schizophrenia (Kasper, 2006), the
long-term outcome for up to 40% of patients remains unsatisfactory
as they continue to suffer from one or more distressing symptoms de-
spite remaining medication compliant (Conley and Kelly, 2001;
Potkin et al., 2009). Additional beneﬁts of cognitive behaviour thera-
py for psychosis (CBTp) have been reported for such patients (re-
views, Pilling et al., 2002; Zimmermann et al., 2005; Pfammatter et
al., 2006; Wykes et al., 2008), and symptom improvement may con-
tinue even after therapy is terminated (Sensky et al., 2000; Sarin ety, P078, Institute of Psychiatry,
8AF, UK. Tel.: +44 207 848
.
 license. al., 2011). CBTp is now recommended for the treatment of psychosis
in both the National Institute for Health and Clinical Excellence
(NICE) updated guidelines in the UK (NICE, 2009) and the Schizo-
phrenia Patient Outcomes Research Team (PORT) Treatment Recom-
mendations in the US (Dixon et al., 2010). The beneﬁcial effects of
CBTp, however, are seen with modest effect sizes and to a meaningful
degree in only about 50% of patients who undergo this therapy
(Pilling et al., 2002; Pfammatter et al., 2006; Wykes et al., 2008).
Uncovering the determinants of effective CBTp may a) help to maxi-
mise its beneﬁts by targeting the most relevant population, and
b) to identify methods to help those who do not show a sufﬁcient re-
sponse with current antipsychotic medications and CBTp.
A number of studies have focussed on speciﬁc predictors of clinical
response to CBTp (Garety et al., 1997; Kumari et al., 2009, 2010;
Penades et al., 2010; Premkumar et al., 2010, 2011). Cognitive ﬂexi-
bility about delusions (Garety et al., 1997), better cognitive insight
(Perivoliotis et al., 2010), and lower conviction scores (Brabban et
al., 2009) have all been found to be predictors of a good outcome on
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positive association between verbal memory and clinical outcome fol-
lowing CBTp. Although we did not ﬁnd a direct association between
symptom improvement following CBTp and pre-therapy cognitive
performance, assessed with a number of tests commonly employed
in schizophrenia research (Premkumar et al., 2011), we did observe
greater hippocampal grey matter volume in CBTp responders, com-
pared to CBTp non-responders in the same sample (Premkumar
et al., 2009). This latter ﬁnding can be regarded consistent with that
of Penades et al. (2010), given the positive association between hip-
pocampal volume and memory in schizophrenia observed across a
number of previous studies (review, Antonova et al., 2004). Further-
more, our functional magnetic resonance imaging (MRI) studies
have demonstrated that pre-therapy brain activity and functional
connectivity between brain regions involved in cognitive ﬂexibility
and self-other distinction predict clinical outcome following CBTp
(Kumari et al., 2009, 2010). Speciﬁcally, we found a positive associa-
tion between CBTp responsiveness and dorsolateral prefrontal cortex
(DLPFC) activity and its connectivity with the cerebellum (Kumari
et al., 2009), most likely mediated by PFC–cerebellum contributions
to executive processing (Bellebaum and Daum, 2007).
The present study aims to further advance this ﬁeld by investigat-
ing the relationship between pre-CBTp level of sensorimotor gating
function, as assessed by prepulse inhibition (PPI) of the acoustic star-
tle response, and the clinical outcome following CBTp. PPI refers to a
response reduction in reaction to a strong startling stimulus, ‘pulse’,
if this is preceded shortly by a prestimulus, ‘prepulse’, too weak to
evoke a measurable startle response itself (Graham, 1975). PPI pro-
vides an operational index of sensorimotor gating: while information
processing resources are targeted at the prepulse, any incoming infor-
mation (i.e. the pulse) is attended to at reduced level, thereby
protecting the processing of the initial stimulus (i.e. the prepulse)
(Geyer et al., 1990). Since the ﬁrst demonstration by Braff et al.
(1978), a large number of studies have shown reduced PPI, on aver-
age, in people with schizophrenia (e.g. those reviewed in Braff et al.,
2001; Meincke et al., 2004; Swerdlow et al., 2006; Kumari et al.,
2007), especially in those who have thought disorder (Perry and
Braff, 1994; Perry et al., 1999), hear uncontrollable voices (Kumari
et al., 2008a) or have poor global functioning (Swerdlow et al.,
2006). Some studies also report small-to-moderate positive associa-
tions between reduced PPI and poor performance on measures of at-
tention (Karper et al., 1996; Kumari et al., 2007) and executive
function, in particular cognitive ﬂexibility (Butler et al., 1991;
Kumari et al., 2007), in schizophrenia, suggesting that deﬁcient gating
may interfere with higher order cognitive function. Given these ob-
servations, and previous ﬁndings indicating that relatively intact
(pre-therapy) executive processing is associated with good clinical
responsiveness to CBT across many disorders, including depression
(Moorey et al., 2001; Julian and Mohr, 2006) and generalized anxiety
disorder (Mohlman and Gorman, 2005), we hypothesised that there
would be a positive association between pre-therapy PPI level and
clinical response to CBTp in patients with schizophrenia. In addition,
we explored the relationship between pre-therapy level of startle ha-
bituation and CBTp response. Reduced habituation has been found in
people with schizophrenia (e.g. Geyer and Braff, 1982; Braff et al.,
1992; Takahashi et al., 2008); it is thought to reﬂect their inability
to ignore the repetitive functionally insigniﬁcant stimuli and to result
in sensory overload (Geyer and Braff, 1987; Geyer et al., 1990).
2. Methods
2.1. Participants and design
The study included 56 outpatients, 54 with paranoid schizophre-
nia and 2 with schizoaffective disorder, who were willing to receive
6–8 months of CBTp in addition to the treatment and care theywere already receiving from mental health professionals. The clinical
diagnosis was made by a trained psychiatrist using the Structured
Clinical Interview for DSM-IV (SCID; First et al., 2002). Of 56 patients,
28 received CBTp for 6–8 months in addition to their usual treatment
(CBTp+TAU group) and 28 continued to receive treatment as usual
(TAU-alone group) during the course of this investigation. This inves-
tigation has been carried out as part of a larger project examining
MRI, neuropsychological and clinical predictors and correlates of re-
sponsiveness to CBTp. The sample of patients included in this report
thus overlaps with the samples examined in our recent reports
(Kumari et al., 2009, 2010, 2011; Premkumar et al., 2009, 2010,
2011). However, none of these published reports examined or
reported any psychophysiological (startle) data.
The patients in the CBTp+TAU and TAU-alone groups were
recruited from the same geographical area (South London, UK) and
were identiﬁed by their local treating psychiatric consultants as suit-
able for CBTp. All included patients were required to be on stable
doses of antipsychotics for ≥2 years and on the present antipsychotic
for >3 months, to receive a rating of ≥60 on the Positive and Nega-
tive Syndrome scale (PANSS) (Kay et al., 1987), and to have at least
one persistent positive symptom (a score of 3 or above on at least
one of the positive symptoms items of the PANSS, which they experi-
enced as distressing).
As described in Kumari et al. (2011), the recruitment of patients
and the creation of study groups followed a cohort case-controlled
design. It involved the following steps: (i) a patient referred by his/
her local consultant and accepted for CBTp by the Psychological Inter-
ventions Clinic for Outpatients with Psychosis (PICuP), South London
and Maudsley NHS Foundation Trust, (ii) study introduced to the pa-
tient by PICuP staff, (iii) patient contacted by a member of the re-
search team if interested in taking part, (iv) if found suitable,
patient recruited as part of the CBTp+TAU group, and (v) another
patient with similar demographic and clinical characteristics (to
that of the patient included in the CBTp+TAU group) recruited for
the TAU-alone group via local consultants and studied over the
same interval as the CBTp+TAU group. With the resources then
available to the South London and Maudsley NHS Foundation Trust,
out of all patients potentially eligible for CBTp, only around 10%
patients were referred for CBTp. There were no explicit biases in
which patients received CBTp. Allocation of CBTp was driven by clin-
ical resource limitations of the NHS Trust and not by patient charac-
teristics. The researchers were independent of clinical decisions
about which patients were referred for CBTp. All patients underwent
clinical assessment at entry and follow-up (6–8 months later).
Of 56 patients, 3 (1 CBTp+TAU, 2 TAU-alone) did not provide
usable startle data. Of remaining 53 patients, 23 patients of the
CBTp+TAU group and 17 patients of the TAU-alone group completed
follow-up clinical assessment, and had remained on the same type
and dosage of antipsychotic medication during the follow-up period.
Table 1 presents clinical and demographic characteristics of the ﬁnal
sample.
The study was approved by the research ethics committee of the
Institute of Psychiatry and the South London and Maudsley NHS
Foundation Trust. All participants provided written informed consent
after the study procedures had been explained to them.
2.2. Cognitive behaviour therapy for psychosis (CBTp) and treatment-as-
usual (TAU) procedures
After baseline clinical and PPI assessments, the CBTp+TAU group
received 6–8 months of CBTp following the procedures described in a
published manual (Fowler et al., 1995). Therapy sessions were con-
ducted weekly or fortnightly, as preferred by the patient, for up to
one hour. Patients received an average of 16 sessions, as recom-
mended by NICE guidelines in the UK (NICE, 2009), at the PICuP clinic.
The therapists were supervised by one of the two investigators (EK,
Table 1
Demographics, task performance, and clinical characteristics of participants.
CBTp+TAU group (n=23, 16 men and 7 women) TAU-alone group (n=17, 14 men and 3 women)
Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.)
Demographics Baseline Follow-up Baseline Follow-up
Age (years) 36.00 (7.66) 39.53 (9.15)
Education (years) 13.78 (2.81) 13.35 (1.54)
Predicted IQa 109.13 (8.14) 106.71 (9.81)
Age at illness onset (years) 23.74 (7.98) 25.65 (8.31)b
PANSS symptoms
Positive symptoms 18.35 (5.16) c15.04 (4.57) 18.71 (3.22) 18.06 (3.09)
Negative symptoms 18.22 (4.88) c15.91 (4.89) 19.53 (3.97) 20.82 (4.17)
General psychopathology 33.35 (7.79) c28.56 (7.86) 34.65 (4.87) 34.64 (6.12)
Total symptoms 69.91 (14.87) c59.52 (16.22) 72.88 (9.26) 73.52 (11.36)
Antipsychotic medication type 20 patients on atypical; 3 on both
atypical and typical antipsychotics
As baseline 14 patients on atypical; 3 on both
atypical and typical antipsychotics
As baseline
Antipsychotic dose in chlorpromazine
equivalents (mg)
521.07 (387.95) 517.33 (344.32)
a National Adult Reading Test (Nelson and Willison, 1991).
b PANSS: Positive and Negative Symptom Scale (Kay et al., 1987).
c Symptom reduction (pb0.05) in the CBTp+TAU, relative to the TAU-alone (no signiﬁcant change in TAU-alone group, p>0.05) group, at follow-up relative to baseline.
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has evidence of good therapy outcomes (Peters et al., 2010).
TAU provided to all patients prior to, and during, the investigation
consisted of management offered by a case management team with a
dedicated care-coordinator who saw the patient on a regular basis, in
addition to a psychiatrist and other specialists, such as a beneﬁts ad-
viser or a vocational advisor, as required.
2.3. Symptom assessment
All patients were rated, using the PANSS (Kay et al., 1987), at entry
(baseline) and then 6–8 months later (follow-up) by an experienced
psychiatrist (DF), who had no role in patient recruitment or clinical
management of the recruited patients and was blind to whether pa-
tients received CBTp or not. Appointments for these assessments
were made by another member of the research team.
2.4. PPI assessment: paradigm and procedure
A commercially available human startle response monitoring sys-
tem (Mark II, SR-Lab, San Diego, California) was used to generate and
deliver the acoustic stimuli, and to record and score the electromyo-
graphic (EMG) activity for 250 ms starting from the onset of the
acoustic startle stimulus. Acoustic stimuli were presented to study
participants binaurally through headphones. The pulse-alone stimu-
lus was a 40-ms presentation of 114-dB (A) white noise and the pre-
pulse stimulus a 20-ms presentation of 85-dB (A) white noise, both
over 70-dB (A) continuous background noise. The session began
with a 5 min acclimatization period consisting of 70 dB (A) continu-
ous white noise. During the experiment, participants received four
blocks of 12 trials each, after an initial pulse alone trial; each block
consisted of three pulse alone trials, three prepulse trials with a 30-
ms prepulse-to-pulse (onset-to-onset) interval, three prepulse trials
with a 60-ms prepulse-to-pulse interval, and three prepulse trials
with a 120-ms prepulse-to-pulse interval presented to participants
in a pseudorandom order with a mean inter-trial interval of 15 s
(range 9–23 s).
The experimental procedures for recording and scoring the startle
reﬂexes were identical to those reported previously (e.g. Kumari et al.,
2008a, 2008b). Eye blink component of the startle was indexed by re-
cording EMG activity of the orbicularis oculi muscle directly beneath
the right eye, by positioning two miniature silver/silver chloride elec-
trodes. Recorded EMG activity was band-pass ﬁltered, as recommended
by the SR-Lab. A 50-hz ﬁlter was used to eliminate the 50-Hz interfer-
ence. The EMG data were at ﬁrst inspected on a trial-by-trial basisofﬂine and then scored, blind to group membership, using the analytic
programme of this system for response amplitude (in arbitrary
analogue-to-digital units) and latencies to response onset and peak. Re-
sponses (b5%) were rejected if the onset and peak latencies differed by
more than 95 ms or when the baseline values shifted by more than 50
units. PPI was computed for each participant separately for each trial
type as (a−b/a)×100, where “a” = pulse-alone amplitude and
“b” = amplitude over prepulse trials. Percent of PPI, rather than abso-
lute amount of PPI (i.e. arithmetic difference between pulse-alone and
prepulse trials), was used since this procedure eliminates the inﬂuence
of individual differences in startle responsiveness.
Participants were told that the experiment was to measure their re-
action to a number of noise-bursts, but no speciﬁc instructions were
given on whether to attend or ignore them. They were requested to
keep their eyes open during the experiment. There was no explicit re-
striction on smoking intake prior to testing but care was taken not to
start PPI experiment for at least 20 min after a patient smoked a ciga-
rette, in order to prevent a state of smoking withdrawal or a heavy in-
take during the testing session that may transiently affect PPI (Kumari
et al., 2001).2.5. Data analysis
2.5.1. Baseline group comparisons
Possible group differences between the ﬁnal CBTp+TAU and
TAU-alone groups in demographic (age, years in education) and clin-
ical variables (age at illness onset, baseline PANSS scores, medication
dose) were analysed using independent sample t-tests. Possible
group differences in the amplitude and habituation of the startle
response over pulse-alone trials were examined by a 2 (Group:
CBTp+TAU, TAU-alone)×4 (Block: 4 blocks, each consisting of
three trials) ANOVA, with Group as a between-subjects and Block as
a within-subjects factor. To examine group differences in PPI, PPI
(%) scores were subjected to a 2 (Group, as above)×3 (Trial type:
30-ms, 60-ms and 120-ms prepulse trials) ANOVA, with Group as a
between-subjects and Trial type as a within-subjects factor. Latencies
to response peak were analysed with a 2 (Group)×4 (Trial Type:
pulse-alone and 3 prepulse trials) ANOVA with Group as a between-
subjects and Trial Type as a within-subjects factor. Habituation, PPI
and latencies to response onset were initially analysed with Sex as
an additional between-subjects factor but no main effect of Sex was
found and Sex did not interact with Group, Block (habituation) and
Trial Type (PPI and latencies to response peak) for any of the vari-
ables. This (Sex) factor was therefore dropped from the ANOVAs.
Table 2
Mean (standard error of the mean, s.e.m.) response amplitudes over the four blocks of
three pulse-alone trials each, PPI and latencies to response peak in CBTp+TAU and
TAU-alone patients.
Startle amplitude
(analogue-to-digit units)
CBTp+TAU group (n=23,
16 men and 7 women)
TAU-alone group (n=17,
14 men and 3 women)
Mean (s.e.m.) Mean (s.e.m.)
Block 1 267.15 (39.61) 229.88 (56.77)
Block 2 211.22 (30.19) 130.09 (23.74)
Block 3 188.69 (31.13) 116.76 (19.49)
Block 4 154.04 (24.00) 101.07 (18.59)
PPI (%)
30-ms 8.97 (4.93) 7.69 (10.33)
60-ms 16.38 (5.36) 23.56 (6.08)
120-ms 35.86 (5.58) 28.74 (9.53)
Latencies to response peak (ms)
Pulse-alone 68.57 (1.25) 68.67 (2.29)
30-ms 62.09 (1.49) 67.39 (2.27)
60-ms 60.50 (1.61) 65.59 (3.28)
120-ms 66.78 (2.31) 66.46 (3.09)
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The change in symptoms from baseline to follow-upwas investigat-
ed using a Group (CBTp+TAU, TAU-alone)×Time (baseline, follow-
up) ANOVA with Group as a between-subjects factor and Time as a
within-subjects factor. A signiﬁcant Group×Time effect was followed
up by paired t-tests on total and sub-scale PANSS scores separately in
the CBTp+TAU and TAU-alone groups. Following the observation of
signiﬁcant symptom reduction in the CBTp+TAU group, but not in
the TAU-alone group, we conﬁrmed the effects of CBTp using ANCOVAs
on symptom change scores (baseline minus follow-up) co-varying for
baseline symptoms.
2.5.3. Association between pre-therapy PPI and symptom improvement
following CBTp
For this analysis, in addition to symptom change scores, we also
computed the degree of change in symptoms as a function of initial
severity, i.e. the residual change in symptoms, by regressing the initial
PANSS (total and sub-scales) scores on follow-up scores, and included
this as a further outcome measure of CBT responsiveness following
the method used by Siegle et al. (2006). The association between
PPI and symptom improvement following CBTp (both absolute and
residual symptom change) was examined using Pearson's correla-
tions. Such correlations were then also performed in the TAU-alone
group and the strength of the signiﬁcant correlation between PPI
and total symptom change in the two groups was compared using
Fisher's z.
2.5.4. Association between pre-therapy startle amplitude and habituation
and symptom improvement following CBTp
Possible associations between the amplitude (mean amplitude
over all pulse-alone trials) and habituation of the response (comput-
ed as % reduction in amplitude from the ﬁrst block, to the last block, of
pulse-alone trials) with symptom improvement following CBTp were
examined using Pearson's correlations. Such correlations were also
performed in the TAU-alone group, and the strength of the correlation
between habituation and total symptom change in the two groups
was compared using Fisher's z.
All analyses were performed by SPSS windows (version 16). Alpha
level for testing signiﬁcance of effects was p=0.05 unless stated
otherwise.
3. Results
3.1. Baseline group comparisons
As shown in Table 1, the ﬁnal CBTp+TAU and TAU-alone groups,
after the loss of some patients from each group, did not differ in age,
education, IQ, age at illness onset, baseline symptoms, antipsychotic
dose (all p values >0.15) .
The two groups showed comparable amplitude and habituation of
the startle response over pulse-alone trials as demonstrated by a signif-
icantmain effect of Block [F (3, 114)=14.77, pb0.001] indicating habit-
uation of the startle response over four blocks [Linear F (1, 38)=18.60,
pb0.001] in both groups, but no signiﬁcant Group [F (1,37)=2.25,
p=0.14] or Group×Block effect [F (1,111)=0.52, p=0.70]. For PPI
too, there was no effect of Group [F (1,38)=0.01; p=0.96] indicating
comparable PPI in the two groups. There was, as found in previous PPI
studies, a signiﬁcant main effect of Trial type [F (2, 76)=16.18,
pb0.001], reﬂecting a linear increase in PPI from 30-ms through 60-
ms to 120-ms prepulse trials [Linear F (1, 38)=34.41, pb0.001], but
no Group×Trial Type interaction [Group×Trial type: F (2, 76)=1.45,
p=0.24]. Finally, the two groups did not differ in the latencies to peak
over the four trial types as there was only a main effect of Trial Type
[F (3, 114)=3.86, p=0.01] and no Group [Group: F (1,38)=1.58,
p=0.22] or Group×Trial type effect [F (1,114)=1.91, p=0.13].
Mean (s.e.m) startle amplitudes for blocks 1–4, PPI for 30-ms, 60-ms,and 120-ms trials, and mean latencies to peak over the pulse-alone
and prepulse trials in the CBTp+TAU and TAU-alone groups are pre-
sented in Table 2.
3.2. Clinical effects of CBTp+TAU vs TAU-alone
As expected given our previous reports from overlapping samples
(Kumari et al., 2009, 2010, 2011; Premkumar et al., 2009, 2010,
2011), CBTp+TAU, but not TAU-alone, patients showed changes in
symptoms from baseline to follow-up [Group×Time: total PANSS
scores, F=7.48, df=1,38, p=0.009; positive symptoms, F=4.94,
p=0.03; negative symptoms, F=6.43, p=0.02; general psychopa-
thology: F=4.25, p=0.04) (Table 1). Only the CBTp+TAU group
showed reduced symptoms at follow-up (total PANSS scores:
t=3.65, df=22, p=0.001; positive symptoms: t=4.42, pb0.001;
negative symptoms: t=2.51, p=0.02; general psychopathology:
t=2.80, p=0.01).
CBTp+TAU versus TAU-alone group differences in symptom im-
provement (change scores) remained signiﬁcant after co-varying for
baseline symptoms (total PANSS scores: F=9.92, df=1,37,
p=0.003; positive symptoms: F=7.51, p=0.009; negative symp-
toms: F=10.78, p=0.002; general psychopathology: F=6.86,
p=0.01). The number of years in education or illness duration was
not associated with CBTp responsiveness (p values>0.40).
3.3. Association between pre-therapy PPI and symptom improvement
following CBTp
Symptom improvement (absolute change) following CBTp for
PANSS total, negative, and general psychopathology scores was sig-
niﬁcantly positively associated with mean PPI (across 30-ms, 60-ms
and 120-ms trials), and with 120-ms PPI when examined separately
at the three intervals (Table 3, Fig. 1). The positive correlation be-
tween improvement following CBTp for PANSS positive scores symp-
toms and pre-therapy PPI failed to reach formal signiﬁcance.
However, the strength of this (pre-therapy PPI — positive symptom
improvement) correlation was not signiﬁcantly weaker than that ob-
served for the PANSS negative and general psychopathology scores
and the strongest correlation occurred for the PANSS total scores, in-
dicating that pre-therapy PPI was associated with post-CBTp im-
provement in PANSS symptoms across all three subscales, rather
than on particular PANSS subscales. Residual symptom reduction
was also positively associated with 120-ms PPI only (Table 3). No sig-
niﬁcant correlations occurred in the TAU-alone group. The strength of
the correlation between pre-therapy PPI and total symptom change
Table 3
Correlations (Pearson's r) between pre-therapy PPI levels and symptom improvement at follow-up.
PANSS symptom
improvement
CBTp+TAU group (n=23; 16 men and 7 women) TAU-alone group (n=17, 14 men and 3 women)
Mean PPI
(across 30-, 60-, 120 ms)
30-ms
PPI
60-ms
PPI
120-ms PPI Mean PPI
(across 30-, 60-, 120 ms)
30-ms
PPI
60-ms
PPI
120-ms
PPI
Absolute change
Positive symptoms 0.316 (M: 0.450; W: 0.141) 0.189 0.270 0.320 (M: 0.325; W: 0.297) −0.084 −0.120 −0.111 −0.007
Negative symptoms 0.407⁎ (M: 0.283; W: 0.774⁎) 0.126 0.191 0.665⁎⁎⁎ (M: 0.477#; W: 0.895⁎) 0.143 0.074 0.196 0.149
General psychopathology 0.420⁎ (M: 0.490; W: 0.208) 0.142 0.222 0.652⁎⁎⁎ (M: 0.582⁎; W: 0.761⁎) 0.109 0.093 0.135 0.084
PANSS total 0.466⁎ (M: 0.509⁎;W: 0.378) 0.176 0.266 0.689⁎⁎⁎ (M: 0.583⁎; W:0.845⁎) 0.085 0.035 0.110 0.101
Residual change
Positive symptoms 0.134 −0.032 0.020 0.326 (M: 0.228; W: 0.467) −0.057 −0.040 −0.142 −0.006
Negative symptoms 0.174 −0.067 −0.034 0.506⁎ (M: 0.085; W: 0.912⁎⁎) 0.059 0.004 0.193 0.019
General psychopathology 0.222 −0.018 0.050 0.491⁎ (M: 0.359; W: 0.714) −0.006 −0.008 0.074 −0.054
PANSS total 0.301 0.033 0.104 0.581⁎⁎ (M: 0.414; W: 0.827⁎) 0.030 0.002 0.084 0.018
M = men; W = women.
# p=0.06.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
236 V. Kumari et al. / Schizophrenia Research 134 (2012) 232–238in the CBTp+TAU group was stronger than that observed in the TAU-
alone group (absolute symptom change, Fisher's z=2.14, p=0.03;
residual symptom change, Fisher's z=1.85, p=0.06). Finally,
although this study does not allow a meaningful analysis of possible
sex-speciﬁc associations between PPI and response to CBTp due to in-
sufﬁcient number of women, the positive PPI-CBTp response associa-
tions, especially with 120-ms PPI, appear to be present in both sexes
(Table 3, Fig. 1).
3.4. Association between pre-therapy startle amplitude and habituation
and symptom improvement following CBTp
The mean pulse-alone amplitude did not correlate signiﬁcantly but
startle habituation showed a positive association with CBTp response
as assessed with reduction from baseline to follow-up in the total
PANSS scores (for improvement in total PANSS symptoms, r=0.430,
p=0.04; positive symptoms, r=0.361, p=0.09; negative symptoms,
r=0.307, p=0.15; general psychopathology, r=0.395, p=0.06). No
correlation between the amplitude or habituation and clinical change
at follow-upwas found in the TAU-alone group (total PANSS symptoms,
r=−0.08; positive symptoms, r=0.11; negative symptoms, r=
−0.012; general psychopathology, r=0.012). The correlation between
pre-therapy habituation and total symptom change in the CBTp+TAU
group was non-signiﬁcantly different from that observed in the
TAU-alone group (Fisher's z=1.55, p=0.12); however, near-zeroSymptom Improvement
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Fig. 1. Scatter plot of 120-ms PPI across PANSS symptom improvement (baseline total
score minus follow-up total score) in the CBTp+TAU group.correlation in the TAU-alone group and signiﬁcantly positive associ-
ation in the TAU+CBTp may argue for a small but true association
between the rate of habituation and CBTp response.
4. Discussion
Supporting our hypothesis, the ﬁnding of this study revealed a
positive association between (pre-therapy) PPI and symptom improve-
ment following CBTp. The PPI level seen in patients of both the CBTp+
TAU and TAU-alone groups, on average, was markedly low relative to
the level of PPI observed in healthy people [reported in Kumari et al.,
2008a; mean (s.e.m) 30-ms PPI=17.44% (5.12), 60-ms=30.75%
(4.85), 120-ms=45.86% (5.24)] who had been tested using the same
paradigm and procedure in parallel to the patients included in this re-
port. As mentioned earlier (Introduction), there is a sizable proportion
of patients who, despite receiving and being compliant with currently
available antipsychotic therapies and having received adjunctive
CBTp, continue to suffer from distressing symptoms. The present ﬁnd-
ing suggests that this sub-group of patients is characterised by dis-
turbed sensorimotor gating function. Those with relatively intact
gating may be better able to ﬁlter out internal stimuli (Kumari et al.,
2008a) and engage more fully during therapy sessions, and in turn
show a better response to CBTp. The inability to suppress intrusive
memories, thoughts and other internal stimuli is considered to be the
behavioural correlates of deﬁcient PPI across psychiatric disorders
(Geyer, 2006).
The relationship between PPI and clinical responsiveness to CBTp
in this study, however, was signiﬁcantly evident only at 120-ms
prepulse-to-pulse intervals. The relationship with 30-ms and 60-ms
PPI, although in the same direction, failed to reach statistical signiﬁ-
cance. There could be two reasons for this. The ﬁrst that there was
simply less power available to detect CBTp response-PPI association
at 30-ms and 60-ms intervals due to a limited range of PPI scores es-
pecially at 30-ms interval. The second possibility is that cognitive pro-
cesses involved in PPI at 120-ms interval, as discussed below, are
particularly relevant to effective CBTp.
PPI is considered primarily to be a pre-attentive mechanism but it
may be susceptible, especially at >60 ms prepulse-to-pulse intervals,
to cognitive processes controlled in a ‘top down’ manner by the cortex
(Hazlett and Buchsbaum, 2001). While active attention to prepulses is
not necessary for PPI to occur (Bluementhal, 1999), actively ‘attended’
prepulses produce more PPI than the ‘ignored’ ones, at prepulse-to-
pulse intervals greater than 60 ms (Dawson et al., 1997; Filion and
Poje, 2003; Jennings et al., 1996; Schell et al., 2000). Studies in
237V. Kumari et al. / Schizophrenia Research 134 (2012) 232–238schizophrenia samples, which assessed PPI at longer than 60 ms inter-
val or examined mean PPI across short and long intervals, have also
shown small-to-modest positive association between PPI and perfor-
mance on the Wisconsin Card Sort Test, which is widely regarded as a
measure of planning and strategy formation (Butler et al., 1991;
Kumari et al., 2007), and negative correlation with distractibility on
the Continuous Performance Test (Karper et al., 1996; Kumari et al.,
2007). Recent studies in healthy subjects have also found greater PPI
in those with superior performance on DPFC-based tasks of planning,
strategy formation, and selective attention (Bitsios and Giakoumaki,
2005; Bitsios et al., 2006; Giakoumaki et al., 2006). We previously
reported a positive association between DLPFC grey matter volumes
and 120-ms PPI in schizophrenia (Kumari et al., 2008b) and stronger
improvement in PANSS symptoms following CBTp in patients with
greater DPLFC activity (Kumari et al. , 2009).
Our ﬁnding may be taken as further evidence that brain areas in-
volved in the top-down processing of information are associated
with CBTp responsiveness (van der Gaag, 2006). However, our
study is limited by a relatively small sample size, and thus requires
replication. Further studies also need to examine whether the ob-
served association between higher pre-therapy PPI and a good out-
come following CBTp is speciﬁc to this particular therapy, or
extends to clinical outcomes following other psychological interven-
tions. In a study by Granholm et al. (2008), cognitive deﬁcits pre-
dicted poorer function overall in older psychotic patients but did
not moderate the effect of cognitive behavioural social skill training
(CBSST). The therapy in their study, however, was targeted speciﬁcal-
ly at social functioning rather than at distress and symptom
reduction.
This study also found a small association between the rate of star-
tle habituation and response to CBTp, despite the fact that it utilised a
relative brief experiment with only 12 pulse-alone stimuli and thus
was not speciﬁcally designed to probe such an association. This ﬁnd-
ing is complementary to the earlier discussed positive association be-
tween PPI and CBTp response and conﬁrms that a reduced ability to
prevent sensory overload is associated with a poor response to CBTp.
The ﬁnding of this study, despite some limitations, may have prac-
tical implications. Recent attempts to discover new drugs for patients
with schizophrenia who remain distressed by their symptoms despite
receiving and being compliant with current antipsychotic medica-
tions have met with limited (if any) success. As suggested very re-
cently by Swerdlow (2011), a more meaningful progress in this ﬁeld
may be made by focusing on targets which can enhance the efﬁcacy
of psychological therapies in this population. It would be valuable,
for example, to examine whether medication which can enhance
PPI (reviews, Swerdlow et al., 2008; Swerdlow, 2011), or psychologi-
cal interventions, such as attention training, which may be able to im-
prove, at least to some extent, attentional modulation of PPI (Scholes
and Martin-Iverson, 2010), help to maximise beneﬁt from CBTp in
such patient groups. In this context, psychophysiological measures,
such as PPI, with high test-retest reliability (review, Swerdlow et al.,
2008) and preferably low measurement error may provide a more
sensitive tool than commonly used neuropsychological tests (often
involving multiple cognitive domains). Neuropsychological tests ap-
pear less sensitive than PPI (and MRI) as predictors of CBTp outcome
(i.e. failed to relate to CBTp response in a highly overlapping sample;
Premkumar et al., 2011).
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